Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 112

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 4
Chunk 112
---
 options.

Tackling a Social Burden to Improve the Lives of Patients and People
Surrounding Them

Alcoholism and binge drinking are a huge social
burden in terms of costs by direct and indirect implications. These health problems impact a wide range of social cycles surrounding the
alcoholic/ binge drinkers life - especially when it is a parent, life partner, sibling or co-worker. According to the National Council
on Alcoholism and Drug Dependence:

The time, effort, and resources formerly dedicated to
life-sustaining activities, such as working and spending time with the family, are disrupted. Initially, a person may think that abusing
alcohol will help them deal with these stressors, but as they continue to drink a lot, over time, this use can turn into dependence on
the substance. Once individuals become psychologically addicted, alcohol abuse can become all-consuming. As individuals are often part
of social networks, it is easy to understand how alcohol abuse has a ripple effect across a person’s entire network of family, friends,
employers, colleagues, and anyone else who depends on the person.

Reducing the problem for the patient will have
a rebound effect, reducing the burden for the patient’s social circle as well.

Lack of Therapeutic Innovation and New Treatments

Historically, there has been a lack of innovation
in new treatments and medicines for the treatment of alcohol related disorders. There are only three medications that are currently FDA-approved
for the treatment of moderate to severe AUD: disulfiram, naltrexone (oral and long-acting injectable formulations), and acamprosate. Both
naltrexone and acamprosate were associated with reduction in relapse to drinking. When directly compared with one another, no significant
differences were found between acamprosate and naltrexone for controlling alcohol consumption. Disulfiram is used as a second-line treatment,
behind acamprosate and naltrexone, for alcohol dependence. Based on results in open-label studies, disulfiram is a safe and efficacious
treatment compared to other abstinence supportive pharmacological treatments or to no disulfiram in supervised studies for problems of
alcohol abuse or dependence. In a meta-analysis conducted on disulfiram use with alcoholics in comparison to any alcoholic control group,
it was concluded that blinded studies with disulfiram were incapable of distinguishing a difference between treatment and control groups.
An additional drug, Nalmef